AI-Generated Summary

Signaturefd LLC significantly reduced its stake in Legend Biotech Corporation, though other institutional investors like GAMMA Investing LLC and Harbor Capital Advisors Inc. increased their positions. The article details Legend Biotech's recent stock performance, including its market capitalization, P/E ratio, and latest quarterly earnings. Wall Street analysts maintain a 'Moderate Buy' rating for LEGN, with a consensus price target of $74.22.

In a nutshell

This report offers a snapshot of institutional sentiment and financial metrics for Legend Biotech, providing healthcare investors with crucial data points for assessing the company's current market position and future outlook. The mixed institutional activity alongside a generally positive analyst consensus suggests a dynamic investment landscape for the clinical-stage biopharmaceutical firm.

Source: ETF Daily News